A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
Authors:
- 11 December 2013
- journal article
- clinical trial
- Published by SAGE Publications in Cephalalgia
- Vol. 34 (7) , 523-532
Abstract
Objective The objective of this article is to see whether the effect of candesartan for migraine prevention, shown in one previous study, could be confirmed in a new study, and if so, whether the effect was comparable to that of propranolol (non-inferiority analysis), and whether adverse events were different. Methods In a randomised, triple-blind, double cross-over study, 72 adult patients with episodic or chronic migraine went through three 12-week treatment periods on either candesartan 16 mg, propranolol slow-release 160 mg, or placebo. The main outcome measures were days with migraine headache per four weeks (primary outcome), days with headache, hours with headache, proportion of responders (>50% reduction of migraine days from baseline), and adverse events. Results In the modified intention-to treat-analysis, candesartan and propranolol were both superior to placebo: 2.95 (95% confidence interval: 2.35–3.55%) and 2.91 (2.36–3.45%), versus 3.53 (2.98–4.08%) for migraine days per month (p = 0.02 for both comparisons, Wilcoxon's paired signed rank test, blinded statistical analysis). Candesartan was non-inferior to propranolol (and vice versa). The proportion of responders was significantly higher on candesartan (43%) and propranolol (40%) than on placebo (23%) (p = 0.025 and n = 133%) and propranolol (n = 143%) than on placebo (n = 90%), and the adverse event profiles of the active substances differed somewhat. Conclusion It is confirmed that candesartan 16 mg is effective for migraine prevention, with an effect size similar to propranolol 160 mg, and with somewhat different adverse events. Trial registration: EUDRACT (2008-002312-7), ClinicalTrials.gov (NCT00884663).Keywords
This publication has 22 references indexed in Scilit:
- GBD 2010: understanding disease, injury, and riskThe Lancet, 2012
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsNeurology, 2012
- The cost of headache disorders in Europe: the Eurolight projectEuropean Journal of Neurology, 2011
- EFNS guideline on the drug treatment of migraine – revised report of an EFNS task forceEuropean Journal of Neurology, 2009
- Migraine prophylaxisMedical Journal of Australia, 2008
- Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in AdultsCephalalgia, 2008
- Impact of headache in Europe: a review for the Eurolight projectThe Journal of Headache and Pain, 2008
- Migraine prevalence, disease burden, and the need for preventive therapyNeurology, 2007
- Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlockerJAMA, 2003
- Guidelines for Controlled Trials of Drugs in Migraine: Second EditionCephalalgia, 2000